Melitracen

Melitracen
Skeletal formula of melitracen
Ball-and-stick model of the melitracen molecule
Clinical data
AHFS/Drugs.com International Drug Names
Routes of
administration		 Oral, IM
ATC code N06AA14 (WHO)
Legal status
Legal status
  • ℞ (Prescription only)
Identifiers
CAS Number 5118-29-6 N
PubChem (CID) 25382
ChemSpider 23697 YesY
UNII Q7T0Y1109Z YesY
KEGG D08171 YesY
ChEMBL CHEMBL110094 YesY
ECHA InfoCard 100.023.507
Chemical and physical data
Formula C21H25N
Molar mass 291.43 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Melitracen (Adaptol, Dixeran, Melixeran, Thymeol, Trausabun) is a tricyclic antidepressant (TCA) marketed in Europe and Japan by Lundbeck and Takeda, respectively, for the treatment of depression and anxiety.[1][2][3][4] In addition to single drug preparations, it is also available as Deanxit, a combination product containing both melitracen and flupentixol.[5][6][7][8]

The pharmacology of melitracen has not been properly investigated and is largely unknown, but it is likely to act in a similar manner to other TCAs. Indeed, melitracen is reported to have imipramine and amitriptyline-like effects and efficacy against depression and anxiety, though with improved tolerability and a somewhat faster onset of action.[9][10]

See also

References

  1. ↑ Swiss Pharmaceutical Society (2000). Index Nominum 2000: International Drug Directory (Book with CD-ROM). Boca Raton: Medpharm Scientific Publishers. ISBN 3-88763-075-0.
  2. ↑ Hall, Chapman and; Chemical Abstracts Service, American Chemical Society; Rhodes, P. H (1996). Dictionary of organic compounds. London: Chapman & Hall. ISBN 0-412-54090-8.
  3. ↑ O'Neil, Maryadele J. (2001). The Merck index: an encyclopedia of chemicals, drugs, and biologicals. Rahway, NJ: Merck Research Laboratories. ISBN 0-911910-13-1.
  4. ↑ José Miguel Vela; Helmut Buschmann; Jörg Holenz; Antonio Párraga; Antoni Torrens (2007). Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application. Weinheim: Wiley-VCH. ISBN 3-527-31058-4.
  5. ↑ Muller, Niels F; Dessing, Rudolf P; Pharmacy, European Society of Clinical (1998). European Drug Index, 4th Edition. Boca Raton: CRC Press. ISBN 3-7692-2114-1.
  6. ↑ Van Moffaert M, Dierick M, De Meulemeester F, Vereecken A (1983). "Treatment of depressive anxiety states associated with psychosomatic symptoms. A double-blind multicentre clinical study: mianserin versus melitracen-flupentixol". Acta Psychiatrica Belgica. 83 (5): 525–39. PMID 6670581.
  7. ↑ Bin Yaacob H (April 1985). "Flupenthixol and Melitracen in the management of trigeminal neuralgia". Dental Journal of Malaysia. 8 (2): 37–8. PMID 3917005.
  8. ↑ Hashash JG, Abdul-Baki H, Azar C, et al. (June 2008). "Clinical trial: a randomized controlled cross-over study of flupenthixol + melitracen in functional dyspepsia". Alimentary Pharmacology & Therapeutics. 27 (11): 1148–55. doi:10.1111/j.1365-2036.2008.03677.x. PMID 18331614.
  9. ↑ Aronson, Jeffrey Kenneth (2008). Meyler's Side Effects of Psychiatric Drugs (Meylers Side Effects). Amsterdam: Elsevier Science. ISBN 0-444-53266-8.
  10. ↑ Author Unknown (1970). Ann Reports Medicinal Chem V5 (v. 5). Boston: Academic Press. ISBN 0-12-040505-9.


This article is issued from Wikipedia - version of the 5/27/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.